Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
Morepen Labs successfully raised Rs. 200 Crore through QIP
Morepen Labs successfully raised Rs. 200 Crore through QIP
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Decision on EU marketing authorisation for this population expected by September 2024
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Subscribe To Our Newsletter & Stay Updated